H Lundbeck A/S (HLUYY) 21.5400 $HLUYY
A New Beginning For Lundbeck, But Not A Clean Start
Stephen Simpson, CFA - at Seeking Alpha - Fri May 08, 8:12AM CDT
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 391.24 (-3.11), MDCO: 26.35 (+0.35), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), LLY: 72.90 (-0.16), ABBV: 65.99 (+0.02), CELG: 115.53 (+0.45)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 126.21 (+3.21), PFE: 33.99 (+0.05), AMGN: 162.36 (+0.38), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), ABBV: 65.99 (+0.02), THRX: 16.25 (+0.18), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42), NVS: 103.75 (-0.15)
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
Business Wire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
Although Undervalued, Lundbeck Likely Stuck Until New Drugs Start Ramping
Stephen Simpson, CFA - at Seeking Alpha - Mon Feb 09, 11:00AM CST
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.24 (-3.11), FWP: 34.65 (+0.24), ALKS: 60.00 (unch), XNPT: 5.94 (+0.01)
Lundbeck Continues To Fight To Stand Out
Stephen Simpson, CFA - at Seeking Alpha - Thu Dec 18, 10:53AM CST
JNJ: 102.30 (+0.47)
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
Business Wire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
Five-Year Data From SABRIL(R) (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
Business Wire - Mon Dec 08, 10:00AM CST
A late-breaking poster presentation focused on five-year vision data from Lundbeck's SABRIL (vigabatrin) patient registry was presented at the annual meeting of the American Epilepsy Society (AES). The data set includes 6,823 patients enrolled from August 21, 2009 through August 26, 2014.(1) The U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of SABRIL-induced permanent vision loss, including an ongoing patient registry.
Lundbeck Partners with the Hereditary Disease Foundation, Pledges Five Additional Years of Support for Build Hope for Huntington's Disease Campaign
Business Wire - Thu Nov 06, 8:00AM CST
Today, Lundbeck and the Hereditary Disease Foundation announced the launch of the fifth annual Build Hope for Huntington's Disease (HD) initiative. The online donation campaign helps support the Casa Hogar Corea de Huntington Amor y Fe (Huntington's Chorea Home of Love and Faith). This clinic provides care for the Venezuelan families who were essential in leading to groundbreaking discoveries in HD and other genetic diseases. To prompt a donation from Lundbeck, visit www.BuildHopeforHD.com or www.hdfoundation.org and click on the campaign icon. For every click before the end of the year, Lundbeck will donate $15 to the clinic, up to $25,000.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
AGN: 240.22 (+2.88), GILD: 109.30 (+0.56), PRAN: 1.23 (+0.02)
Is Alkermes plc Stock Undervalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
In simple terms, what Alkermes plc is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent...
JNJ: 102.30 (+0.47), ALKS: 60.00 (unch)
A New Beginning For Lundbeck, But Not A Clean Start
Stephen Simpson, CFA - at Seeking Alpha - Fri May 08, 8:12AM CDT
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 391.24 (-3.11), MDCO: 26.35 (+0.35), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), LLY: 72.90 (-0.16), ABBV: 65.99 (+0.02), CELG: 115.53 (+0.45)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 126.21 (+3.21), PFE: 33.99 (+0.05), AMGN: 162.36 (+0.38), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), ABBV: 65.99 (+0.02), THRX: 16.25 (+0.18), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42), NVS: 103.75 (-0.15)
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
Business Wire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
Although Undervalued, Lundbeck Likely Stuck Until New Drugs Start Ramping
Stephen Simpson, CFA - at Seeking Alpha - Mon Feb 09, 11:00AM CST
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.24 (-3.11), FWP: 34.65 (+0.24), ALKS: 60.00 (unch), XNPT: 5.94 (+0.01)
Lundbeck Continues To Fight To Stand Out
Stephen Simpson, CFA - at Seeking Alpha - Thu Dec 18, 10:53AM CST
JNJ: 102.30 (+0.47)
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
Business Wire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
Five-Year Data From SABRIL(R) (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
Business Wire - Mon Dec 08, 10:00AM CST
A late-breaking poster presentation focused on five-year vision data from Lundbeck's SABRIL (vigabatrin) patient registry was presented at the annual meeting of the American Epilepsy Society (AES). The data set includes 6,823 patients enrolled from August 21, 2009 through August 26, 2014.(1) The U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of SABRIL-induced permanent vision loss, including an ongoing patient registry.
Lundbeck Partners with the Hereditary Disease Foundation, Pledges Five Additional Years of Support for Build Hope for Huntington's Disease Campaign
Business Wire - Thu Nov 06, 8:00AM CST
Today, Lundbeck and the Hereditary Disease Foundation announced the launch of the fifth annual Build Hope for Huntington's Disease (HD) initiative. The online donation campaign helps support the Casa Hogar Corea de Huntington Amor y Fe (Huntington's Chorea Home of Love and Faith). This clinic provides care for the Venezuelan families who were essential in leading to groundbreaking discoveries in HD and other genetic diseases. To prompt a donation from Lundbeck, visit www.BuildHopeforHD.com or www.hdfoundation.org and click on the campaign icon. For every click before the end of the year, Lundbeck will donate $15 to the clinic, up to $25,000.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
AGN: 240.22 (+2.88), GILD: 109.30 (+0.56), PRAN: 1.23 (+0.02)
Is Alkermes plc Stock Undervalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
In simple terms, what Alkermes plc is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent...
JNJ: 102.30 (+0.47), ALKS: 60.00 (unch)
